{
    "nctId": "NCT04524728",
    "briefTitle": "Patterns of Treatment and Outcome of Palbociclib Plus Endocrine Therapy",
    "officialTitle": "Patterns of Treatment and Outcome of Palbociclib Plus Endocrine Therapy in Hormone Receptor-positive (HR+)/HER2 Receptor-negative (HER2-) Metastatic Breast Cancer (MBC): a Real World Multicentre Italian Study",
    "overallStatus": "COMPLETED",
    "conditions": "Breast, Neoplasm Malignant, Female",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 191,
    "primaryOutcomeMeasure": "Clinical Benefit Rate (CBR)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Pre- and postmenopausal women with a histologically proven HR+MBC, candidate to receive palbociclib plus ET as first or subsequent line of therapy according to their contingent clinical situation.\n* HER2- disease (IHC 0-1 or IHC 2, confirmed as FISH negative), presence of measurable or evaluable lesions and life expectancy of at least 4 months.\n* Adequate bone marrow, hepatic and renal function, according to clinical practice guidelines for antineoplastic drug administration\n\nExclusion Criteria:\n\n* ER- PgR- disease\n* HER2+ disease (IHC 3 or IHC 2, confirmed as FISH positive)\n* Any cardiovascular, renal or hepatic condition that would compromise conditions in the opinion of the investigator",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}